Research Article
Year 2025,
Volume: 50 Issue: 2, 390 - 399, 30.06.2025
Abstract
Amaç: Bu çalışmanın amacı subklinik hipotiroidizmin chemerin ve Sfrp5 düzeyleri üzerindeki etkisini araştırmaktır.
Gereç ve Yöntem: Subklinik hipotiroidi tanısı alan 46 birey hasta grubu, 49 sağlıklı birey ise kontrol grubu olarak çalışmaya katıldı. Serum Chemerin ve Sfrp5 düzeyleri ELISA yöntemiyle çalışıldı. Bireylerin eş zamanlı olarak alınan kanda çalışılan LDL kolesterol, total kolesterol, trigliserid, HDL kolesterol, insülin, glukoz düzeyleri ise hasta dosya bilgisinden alındı.
Bulgular: Hasta grubunda yapılan Spearman korelasyon analizinde Chemerin ve Sfrp5 düzeyleri arasında istatistiksel olarak anlamlı pozitif korelasyon tespit edildi (r = 0,704). Hasta ve kontrol grupları birlikte değerlendirilerek yapılan Spearman korelasyon analizinde ise, Chemerin ve Sfrp5 düzeyleri arasında anlamlı pozitif korelasyon bulunurken (r = 0,814) ; Sfrp5 ile LDL kolesterol, total kolesterol, trigliserid, vücut kitle indeksi, diyastolik kan basıncı ve sistolik kan basıncı değerleri arasında negatif korelasyonlar tespit edildi (r = -0,320, r = -0,341, r = -0,278, r = -0,383, r = -0,230, and r = -0,206, respectively).
Sonuç: Subklinik hipotiroidizmde inflamatuvar belirteç olan Chemerin düzeyinde artış, antiinflamatuvar belirteç olan Sfrp5 düzeyinde azalma olmasına rağmen bu değişiklik istatistiksel olarak anlamlı bulunmadı. Subklinik hipotiroidizm gelişiminde adipokinlerin ve inflamasyonun etkilerini ortaya koymak ve bu iki parametrenin biyobelirteç olarak kullanılıp kullanılmayacağını anlamak için daha fazla katılımcı ile yeni çalışmalara ihtiyaç vardır.
Keywords
Project Number
1
References
- Korbonits M. Leptin and the thyroid - a puzzle with missing pieces. Clin Endocrinol. 1998;49:569-72.
- Knudsen N, Jorgensen T, Rasmussen S, Christiansen E, Perrild H. The prevalence of thyroid dysfunction in a population with borderline iodine deficiency. Clin Endocrinol. 1999;51:361-7.
- Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S, Lombardi G. Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol. 2005;152:1-9.
- Ross D. Subclinical hypothyroidism. In: Braverman LE, Utiger RD (eds). Werner and Ingbar’s the thyroid: a fundamental and clinical text. 8th ed: 1070-1078. Philadelphia, Lippincott Williams & Wilkins. 2005.
- Hollowell J, Staehling N, Flanders W, Hannon W, Gunter E, Spencer C. Serum tsh, t4, and thyroid antibodies in the United States population: National health and nutrition examination survey. J Clin Endocrinol Metab. 2002;87:489-99.
- Cooper DS. Clinical practice. Subclinical hypothyroidism. N Engl J Med. 2001;345:260-65.
- Vanderpump MP, Tunbridge WM. Epidemiology and prevention of clinical and subclinical hypothyroidism. Thyroid. 2002;12:839-47.
- Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228-38.
- Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med. 2002;137:904-14.
- Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam study. Ann Intern Med. 2000;132:270-78.
- Danese MD, Ladenson PW, Meinert CL, Powe NR. Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab. 2000;85:2993-3001.
- Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160:526-34.
- Kong WM, Sheikh MH, Lumb PJ, Naoumova RP, Freedman DB, Crook M et al. A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. Am J Med. 2002;112:348-54.
- Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey. Clin Endocrinol (Oxf). 1995;43:55-68.
- Huber G, Staub JJ, Meier C, Mitrache C, Guglielmetti M, Huber P et al. Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve and thyroid antibodies. J Clin Endocrinol Metab. 2002;87:3221-6.
- Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Poul E, Migeotte I et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003;198:977-85.
- Booth A, Magnuson A, Fouts J, Foster M. Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Investig. 2015;21:57-74.
- Rourke JL, Dranse HJ, Sinal CJ. Towards an integrative approach to understanding the role of chemerin in human health and disease. Obes Rev. 2013;14:245-62.
- Chang JT, Esumi N, Moore K, Li Y, Zhang S, Chew C et al. Cloning and characterization of a secreted frizzled-related protein that is expressed by the retinal pigment epithelium. Hum Mol Genet. 1999;8:575-83.
- Ouchi N, Higuchi A, Ohashi K, Oshima Y, Gokce N, Shibata R et al. Sfrp5 is an antiinflammatory adipokine that modulates metabolic dysfunction in obesity. Science. 2010;329:454-7.
- Satoh W, Matsuyama M, Takemura H, Aizawa S, Shimono A. Sfrp1, sfrp2, and sfrp5 regulate the Wnt/β-catenin and the planar cell polarity pathways during early trunk formation in mouse. Genesis. 2008;46:92-103.
- Cho YK, Kim HJ, Park JY, Ro H, Chang JH, Lee HH et al. Effect of sfrp5 (secreted frizzled-related protein 5) on the wnt5a (wingless-type family member 5a)-induced endothelial dysfunction and its relevance with arterial stiffness in human subjects. Arterioscler Thromb Vasc Biol. 2018;38:1358-67.
- Liu W, Wang X, Gong L, Zhang Y, Li J, Chen Y et al. Sfrp5 mediates downregulation of the wnt5a/caveolin-1/jnk signaling pathway. J Endocrinol. 2020;247:263-72.
- Assiri AMA, Kamel HFM, Hassanien MFR. Resistin, visfatin, adiponectin, and leptin: risk of breast cancer in pre- and postmenopausal saudi females and their possible diagnostic and predictive implications as novel biomarkers. Dis Markers. 2015;2015:253519.
- Balkau B, Charles MA. Comment on the provisional report from the who consultation. European group for the study of ınsulin resistance. Diabet Med. 1999;16:442-3.
- Berta E, Harangi M, Varga VE, Lőrincz H, Seres I, Nagy EV et al. Evaluation of serum chemerin level in patients with hashimoto's thyroiditis. J Atherosclerosis. 2016;252:e168.
- Tamer S, Turan T, Taşkan T, Karakoç MA, Arslan İE, Gönenç A. Serum chemerin, vaspin, oxidative stress and inflammation markers in subclinical hypothytoidism/hyperthyroidism. JBACHS. 2004;8:296-307.
- Alshaikh EM, Omar UM, Alsufiani HM, Alzahrani OA, Al-Hussein KA, Al-Amri AM et al. The potential influence of hyperthyroidism on circulating adipokines chemerin, visfatin, and omentin. Int J Health Sci. 2019;13:44-7.
- Lehrke M, Becker A, Greif M, Stark R, Laubender RP, Ziegler FV et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol. 2009;161:339-44.
- Chen X, Gao C, Gong N, Wang Y, Tian L. The change of left ventricular function in rats with subclinical hypothyroid and the effects of thyroxine replacement. Int J Endocrinol. 2018;2018:2968670.
- Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007;282:28175-88.
- Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jovett J, Collier G et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007;148:4687-94.
- Xu Q, Wang H, Li Y, Zhang Y, Liu Y, Chen X et al. Plasma sfrp5 levels correlate with determinants of the metabolic syndrome in Chinese adults. Diabetes Metab Res Rev. 2017;33:e2904.
- Hu W, Li L, Yang M, Luo X, Ran W, Liu D et al. Circulating sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans. J Clin Endocrinol Metab. 2013;98:290-8.
- Gao Y, Sheng M, Zhao Y, Jiang H, Zhang Y. Serum chemerin and thyrotropin expression levels in patients with thyroid cancer and roles in predicting survival. Int J Clin Exp Med. 2019;12:7561-8.
- Yang M, Yang G, Dong J, Liu Y, Zong H, Liu H et al. Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension. J Investig Med. 2010;58:883-6.
- Li Y, Shi B, Li S. Association between serum chemerin concentrations and clinical indices in obesity or metabolic syndrome: a meta-analysis. PLoS One. 2014;9:e113915.
- Stejskal D, Karpisek M, Hanulova Z, Svestak M. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population – a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008;152:217-21.
Year 2025,
Volume: 50 Issue: 2, 390 - 399, 30.06.2025
Abstract
Purpose:. This study aimed to investigate the impact of subclinical hypothyroidism on chemerin and Sfrp5 levels.
Material and Methods: Forty-six individuals with subclinical hypothyroidism were enrolled in the patient group, and 49 healthy individuals were included as controls. Serum levels of chemerin and Sfrp5 were measured using the ELISA method. LDL cholesterol, total cholesterol, triglycerides, HDL cholesterol, insulin, and glucose levels were simultaneously measured in blood samples and obtained from patients' medical records.
Results: In the patient group, a statistically significant positive correlation was found between chemerin and Sfrp5 levels in the Spearman correlation analysis (r = 0.704). When both the patient and control groups were evaluated together, a significant positive correlation was observed between chemerin and Sfrp5 levels (r = 0.814). Additionally, negative correlations were found between Sfrp5 and LDL cholesterol, total cholesterol, triglycerides, body mass index, diastolic blood pressure, and systolic blood pressure (r = -0.320, r = -0.341, r = -0.278, r = -0.383, r = -0.230, and r = -0.206, respectively).
Conclusion: In subclinical hypothyroidism, chemerin, an inflammatory marker, tended to be elevated, while Sfrp5, an anti-inflammatory marker, tended to be reduced; however, these changes were not statistically significant. Further studies with larger sample sizes are needed to clarify the role of adipokines and inflammation in the development of subclinical hypothyroidism and to assess whether these parameters could serve as potential biomarkers.
Keywords
Ethical Statement
Ethical approval for the study was obtained from the OMU Faculty of Medicine Clinical Studies Ethics Committee ( SAMSUN OMU KAEK 2020/98).
Supporting Institution
The kits and materials used in this study were provided with funding from SAMSUN OMU BAP (PYO.TIP.1904.20.005).
Project Number
1
References
- Korbonits M. Leptin and the thyroid - a puzzle with missing pieces. Clin Endocrinol. 1998;49:569-72.
- Knudsen N, Jorgensen T, Rasmussen S, Christiansen E, Perrild H. The prevalence of thyroid dysfunction in a population with borderline iodine deficiency. Clin Endocrinol. 1999;51:361-7.
- Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S, Lombardi G. Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol. 2005;152:1-9.
- Ross D. Subclinical hypothyroidism. In: Braverman LE, Utiger RD (eds). Werner and Ingbar’s the thyroid: a fundamental and clinical text. 8th ed: 1070-1078. Philadelphia, Lippincott Williams & Wilkins. 2005.
- Hollowell J, Staehling N, Flanders W, Hannon W, Gunter E, Spencer C. Serum tsh, t4, and thyroid antibodies in the United States population: National health and nutrition examination survey. J Clin Endocrinol Metab. 2002;87:489-99.
- Cooper DS. Clinical practice. Subclinical hypothyroidism. N Engl J Med. 2001;345:260-65.
- Vanderpump MP, Tunbridge WM. Epidemiology and prevention of clinical and subclinical hypothyroidism. Thyroid. 2002;12:839-47.
- Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228-38.
- Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med. 2002;137:904-14.
- Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam study. Ann Intern Med. 2000;132:270-78.
- Danese MD, Ladenson PW, Meinert CL, Powe NR. Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab. 2000;85:2993-3001.
- Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160:526-34.
- Kong WM, Sheikh MH, Lumb PJ, Naoumova RP, Freedman DB, Crook M et al. A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. Am J Med. 2002;112:348-54.
- Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey. Clin Endocrinol (Oxf). 1995;43:55-68.
- Huber G, Staub JJ, Meier C, Mitrache C, Guglielmetti M, Huber P et al. Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve and thyroid antibodies. J Clin Endocrinol Metab. 2002;87:3221-6.
- Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Poul E, Migeotte I et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003;198:977-85.
- Booth A, Magnuson A, Fouts J, Foster M. Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Investig. 2015;21:57-74.
- Rourke JL, Dranse HJ, Sinal CJ. Towards an integrative approach to understanding the role of chemerin in human health and disease. Obes Rev. 2013;14:245-62.
- Chang JT, Esumi N, Moore K, Li Y, Zhang S, Chew C et al. Cloning and characterization of a secreted frizzled-related protein that is expressed by the retinal pigment epithelium. Hum Mol Genet. 1999;8:575-83.
- Ouchi N, Higuchi A, Ohashi K, Oshima Y, Gokce N, Shibata R et al. Sfrp5 is an antiinflammatory adipokine that modulates metabolic dysfunction in obesity. Science. 2010;329:454-7.
- Satoh W, Matsuyama M, Takemura H, Aizawa S, Shimono A. Sfrp1, sfrp2, and sfrp5 regulate the Wnt/β-catenin and the planar cell polarity pathways during early trunk formation in mouse. Genesis. 2008;46:92-103.
- Cho YK, Kim HJ, Park JY, Ro H, Chang JH, Lee HH et al. Effect of sfrp5 (secreted frizzled-related protein 5) on the wnt5a (wingless-type family member 5a)-induced endothelial dysfunction and its relevance with arterial stiffness in human subjects. Arterioscler Thromb Vasc Biol. 2018;38:1358-67.
- Liu W, Wang X, Gong L, Zhang Y, Li J, Chen Y et al. Sfrp5 mediates downregulation of the wnt5a/caveolin-1/jnk signaling pathway. J Endocrinol. 2020;247:263-72.
- Assiri AMA, Kamel HFM, Hassanien MFR. Resistin, visfatin, adiponectin, and leptin: risk of breast cancer in pre- and postmenopausal saudi females and their possible diagnostic and predictive implications as novel biomarkers. Dis Markers. 2015;2015:253519.
- Balkau B, Charles MA. Comment on the provisional report from the who consultation. European group for the study of ınsulin resistance. Diabet Med. 1999;16:442-3.
- Berta E, Harangi M, Varga VE, Lőrincz H, Seres I, Nagy EV et al. Evaluation of serum chemerin level in patients with hashimoto's thyroiditis. J Atherosclerosis. 2016;252:e168.
- Tamer S, Turan T, Taşkan T, Karakoç MA, Arslan İE, Gönenç A. Serum chemerin, vaspin, oxidative stress and inflammation markers in subclinical hypothytoidism/hyperthyroidism. JBACHS. 2004;8:296-307.
- Alshaikh EM, Omar UM, Alsufiani HM, Alzahrani OA, Al-Hussein KA, Al-Amri AM et al. The potential influence of hyperthyroidism on circulating adipokines chemerin, visfatin, and omentin. Int J Health Sci. 2019;13:44-7.
- Lehrke M, Becker A, Greif M, Stark R, Laubender RP, Ziegler FV et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol. 2009;161:339-44.
- Chen X, Gao C, Gong N, Wang Y, Tian L. The change of left ventricular function in rats with subclinical hypothyroid and the effects of thyroxine replacement. Int J Endocrinol. 2018;2018:2968670.
- Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007;282:28175-88.
- Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jovett J, Collier G et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007;148:4687-94.
- Xu Q, Wang H, Li Y, Zhang Y, Liu Y, Chen X et al. Plasma sfrp5 levels correlate with determinants of the metabolic syndrome in Chinese adults. Diabetes Metab Res Rev. 2017;33:e2904.
- Hu W, Li L, Yang M, Luo X, Ran W, Liu D et al. Circulating sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans. J Clin Endocrinol Metab. 2013;98:290-8.
- Gao Y, Sheng M, Zhao Y, Jiang H, Zhang Y. Serum chemerin and thyrotropin expression levels in patients with thyroid cancer and roles in predicting survival. Int J Clin Exp Med. 2019;12:7561-8.
- Yang M, Yang G, Dong J, Liu Y, Zong H, Liu H et al. Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension. J Investig Med. 2010;58:883-6.
- Li Y, Shi B, Li S. Association between serum chemerin concentrations and clinical indices in obesity or metabolic syndrome: a meta-analysis. PLoS One. 2014;9:e113915.
- Stejskal D, Karpisek M, Hanulova Z, Svestak M. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population – a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008;152:217-21.
There are 38 citations in total.
Details
| Primary Language | English |
|---|---|
| Subjects | Clinical Chemistry |
| Journal Section | Research |
| Authors | |
| Project Number | 1 |
| Publication Date | June 30, 2025 |
| Submission Date | January 22, 2025 |
| Acceptance Date | May 23, 2025 |
| Published in Issue | Year 2025 Volume: 50 Issue: 2 |
This journal is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.